99038-33-2Relevant academic research and scientific papers
Platinum(II) complexes catalyze reactions between platinum(IV) complexes and 9-methylxanthine
Roat, Rosette M.,Jerardi, Maria J.,Kopay, Catherine B.,Heath, Danica C.,Clark, Jessica A.,DeMars, Jessa A.,Weaver, John M.,Bezemer, Ernst,Reedijk, Jan
, p. 3615 - 3621 (1997)
Reactions between 9-methylxanthine (9-mxan) and platinum(IV) complexes having ammine, organic amine and chloro ligands are speeded up dramatically by additions of small amounts of the analogous platinum(II) complex. Complexes studied include cis-dichlorodiammineplatinum(II) {cis-[Pt(NH3)2Cl2] 1a}, cis-tetrachlorodiammine-platinum(IV) {cis-[Pt(NH3)2Cl4] 1b}, cis-dichloroammine(cyclohexylamine)platinum(II) {cis-[Pt(NH3)(cha)Cl2] 2a}, cis-tetrachloroammine(cyclohexylamine)platinum(IV) {cis-[Pt(NH3)(cha)Cl4] 2b}, chloro(diethylenetriamine)-platinum(II) chloride {[Pt(dien)Cl]Cl 3a} and mer-trichloro(diethylenetriamine)platinum(IV) chloride {mer-[Pt(dien)Cl3]Cl 3b}. For a 10:90 molar ratio of 1a:1b, the half-life for platinum(IV) - 9-mxan product formation is approximately 3 h whereas t1/2 for pure 1b-9-mxan product formation is greater than 90 h, indicating a 30 times rate enhancement upon addition of 10% of the platinum(II) complex. For the 2a:2b pair, an eight-fold rate enhancement is observed over that for pure 2b-9-mxan. This behavior may be related to the chloride bridging mechanism first elucidated for platinum-(II) and -(IV) complexes. Since known platinum-(II) and -(IV) antitumor drugs target nucleobases of DNA to effect cell death in malignant cells, the reactions discussed may shed light on platinum antitumor compound reaction mechanisms.
Studies on the oral anticancer drug JM-216: Synthesis and characterization of isomers and related complexes
Barnard, Christopher F. J.,Vollano, Jean F.,Chaloner, Penny A.,Dewa, Shaliza Z.
, p. 3280 - 3284 (2008/10/09)
The complex cis,trans,cis-[PtCl2(OAc)2NH3(c-C 6H11NH2)] (JM-216) is currently undergoing clinical evaluation as an antitumor agent. In support of characterization and analysis of this complex a study of its isomers and other complexes [PtClm(OAc)4-mNH3(c-C6H 11NH2)] (m = 0-4) has been undertaken. The complexes have been obtained by a variety of synthetic routes which now extend the scope for the preparation of platinum(IV) antitumor complexes. As platinum(IV) complexes are very stable to substitution in the absence of catalysis, use has been made of both light and base catalysis to promote substitution. Oxidative addition to platinum(II) using hypervalent iodine reagents has also been used. The stereochemistry of the complexes has been confirmed by spectroscopic studies, primarily NMR including natural abundance 15N NMR spectroscopy.
